1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
199.65 USD   +3.40%
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's Disease to FDA
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BIOGEN INC.
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
CI
05/04Michel Vounatsos to Step Down as Chief Executive Officer of Biogen
CI
05/04Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating
MT
05/04Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating
MT
05/04RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating
MT
05/04Barclays Adjusts Biogen's Price Target to $210 From $219, Keeps Equalweight Rating
MT
05/04Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Mainta..
MT
05/03Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.
CI
05/03Change at the top for Biogen after Alzheimer's drug flops
AQ
More most relevant news
All news about BIOGEN INC.
05/12Roche believes cancer drug setback not a fatal blow to growth prospects
RE
05/10Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D..
MT
05/09Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of..
CI
05/05Japanese shares rise on energy, financials boost
RE
05/05Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait ..
MT
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T..
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
More news
News in other languages on BIOGEN INC.
05/12Roche estime que l'échec d'un médicament contre le cancer ne porte pas un coup fatal au..
05/10Selon Biogen, Eisai soumet à la FDA une demande de licence de produit biologique pour l..
05/09Eisai achève la soumission à la FDA américaine de la demande de licence de produit biol..
05/05Biogen s'associe à MedRhythms pour développer et commercialiser un traitement potentiel..
05/05Biogen et MedRhythms vont développer et commercialiser une thérapie numérique sur ordon..
05/04Michel Vounatsos va quitter son poste de directeur général de Biogen
05/04BIOGEN : le flop du médicament Alzheimer aura coûté sa place au DG
05/04PLANÈTE BOURSE - MERCREDI 4 MAI : Amazon pour l'avortement, Western Digital sous pression,..
05/03Wall Street timidement au-dessus de l'équilibre à la veille de la Fed
05/03Les résultats trimestriels de Biogen chutent alors que le fabricant de médicaments prév..
More news
Analyst Recommendations on BIOGEN INC.
05/04Morgan Stanley Adjusts Biogen's Price Target to $285 from $283, Keeps Overweight Rating
MT
05/04Oppenheimer Adjusts Biogen Price Target to $225 From $240, Maintains Outperform Rating
MT
05/04RBC Raises Price Target on Biogen to $251 From $244, Maintains Outperform Rating
MT
05/04Barclays Adjusts Biogen's Price Target to $210 From $219, Keeps Equalweight Rating
MT
05/04Wedbush Trims Biogen's Price Target to $185 From $188, Citing Aduhelm Wind-Down, Mainta..
MT
More recommendations
Press releases
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
BU
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
GL
05/05Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T..
AQ
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/03BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
More press releases
Upcoming event on BIOGEN INC.